Many pharma businesses understand the significance of serialization and have taken the necessary steps to prepare for the important legislation. However, a recent survey has found that not one of the EU Falsified Medicines Directive (FMD) pharma companies describing themselves as ‘very ready’ for serialization, are integrated with their contract manufacturing organisations (CMOs).

Dexter Tjoa, Director Corporate Strategy, has spoken to European Pharmaceutical Manufacturer to outline the challenges that pharma businesses are facing today. Alongside other industry leaders, he discusses how problems such as timing, engaging with trading partners and finding fully compliant solutions can hinder many companies.

You can read the article in full here.